German biopharmaceutical company CureVac (NASDAQ:CVAC) has said its potential vaccine against COVID-19, known as CVnCoV, induced an immune response in pre-clinical animal studies, Reuters news agency reported on Friday.
According to CureVac, CVnCoV produced neutralising antibodies and activated T-cells in hamsters and mice.
The new vaccine, which is being tested in humans in early and mid-stage trials, also protected the lungs of hamsters when they were exposed to a live virus, the company said.
CureVac chief technology officer Mariola Fotin-Mleczek was quoted as saying: "The pre-clinical data published today show that our COVID-19 vaccine candidate has the potential to induce an efficacious and balanced immune response, mimicking the natural immune defence and providing lung protection in a relevant challenge model."
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Yuyu Pharma invests in Dalan Animal Health
Avetra unveils site-centric CRO operating model
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses
Zoetis announces EU approval for Portela to relieve osteoarthritis pain in cats
4basebio synthetic DNA used in Phase I/II mRNA therapy trial